Health Blueprint

Back to Longevity News

News summary

Novo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026

Source: PR Newswire • Published: 06 Nov 2026, 20:07

Summarized by Masters of Longevity from PR Newswire.

Observational analyses found semaglutide 2.4 mg linked to lower liver enzymes, weight, and HbA1c.

Novo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026
Key Takeaways
  • Semaglutide 2.4 mg was associated with greater weight loss.
  • Semaglutide 2.4 mg was associated with larger ALT and AST reductions.
  • Observational data showed semaglutide 2.4 mg improved HbA1c.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.